Genfit SA

GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024

13 ноя 2024 15:10:00 Источник Nasdaq GlobeNewswire

GENFIT Reports Third Quarter 2024 Financial Information

07 ноя 2024 15:10:00 Источник Nasdaq GlobeNewswire

GENFIT: Ipsen’s Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval

23 сен 2024 00:30:00 Источник Nasdaq GlobeNewswire

GENFIT Reports First Half-Year 2024 Financial Results and Provides Corporate Update

19 сен 2024 15:10:00 Источник Nasdaq GlobeNewswire

GENFIT: Positive Opinion from EMA Committee for Ipsen’s Iqirvo® (elafibranor) in Primary Biliary Cholangitis

26 июл 2024 06:45:00 Источник Nasdaq GlobeNewswire

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

09 июл 2024 15:10:00 Источник Nasdaq GlobeNewswire

GENFIT: New EASL-EASD-EASO Clinical Practice Guidelines for MASLD Include NIS2+® as Key Tool for Detecting At-Risk MASH

17 июн 2024 15:10:00 Источник Nasdaq GlobeNewswire

GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen’s Iqirvo® for Primary Biliary Cholangitis

10 июн 2024 16:22:00 Источник Nasdaq GlobeNewswire

GENFIT to Present Latest ACLF Research at EASL Congress™ 2024

29 май 2024 15:10:00 Источник Nasdaq GlobeNewswire

GENFIT: May 22, 2024 Combined Shareholders Meeting Results

22 май 2024 11:05:00 Источник Nasdaq GlobeNewswire

GENFIT Reports First Quarter 2024 Financial Information

14 май 2024 15:10:00 Источник Nasdaq GlobeNewswire

GENFIT: Publication of the 2024 Extra-Financial Performance Report (fiscal year 2023)

25 апр 2024 15:10:00 Источник Nasdaq GlobeNewswire

GENFIT Annual Combined General Meeting of May 22, 2024 — Availability of Preparatory Documents

15 апр 2024 15:10:00 Источник Nasdaq GlobeNewswire

GENFIT Announces Publication of the 2023 Universal Registration Document and the 2023 Annual Report on Form 20-F

05 апр 2024 13:00:00 Источник Nasdaq GlobeNewswire

GENFIT Reports Full-Year 2023 Financial Results and Provides Corporate Update

04 апр 2024 15:10:00 Источник Nasdaq GlobeNewswire

GENFIT Announces Revenues and Cash Position as of December 31, 2023

29 фев 2024 15:10:00 Источник Nasdaq GlobeNewswire

GENFIT Announces 2024 Financial Calendar  

15 янв 2024 15:10:00 Источник Nasdaq GlobeNewswire

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

11 янв 2024 15:10:00 Источник Nasdaq GlobeNewswire

GENFIT Updates 2024 Outlook Following Acceptance of Elafibranor Filings in Primary Biliary Cholangitis (PBC)

08 дек 2023 00:55:00 Источник Nasdaq GlobeNewswire

Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC

07 дек 2023 04:15:01 Источник Nasdaq GlobeNewswire